GlassScriptPhysician profile
Daniela A Kantcheva
NPI 1124072350
$6,196.19
in general payments reported to CMS, 2019-2025
17 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $471 · 2022: $860 · 2023: $972 · 2024: $1,262 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,837 · Education: $28.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,836.83 |
| Education | $28.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.29 | 2021-2025 | |
| Alkermes, INC. | $1,265.61 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $751.77 | 2021-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $526.78 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $447.26 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $373.76 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $286.34 | 2022-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $277.08 | 2022-2025 | Caplyta |
| Lundbeck LLC | $248.51 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $234.46 | 2024-2025 | Cobenfy |
| Indivior INC. | $112.57 | 2022-2024 | Perseris |
| Axsome Therapeutics, INC. | $102.33 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $99.90 | 2023-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $63.17 | 2022-2023 | Belsomra |
| Braeburn INC. | $59.89 | 2024-2025 | Brixadi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hollister Incorporated | $33.53 | 2021 | |
| Idorsia Pharmaceuticals US INC | $25.94 | 2022-2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Kantcheva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.